Report Type: Industry Trends
Report Category: Research Insights
Report Subcategory: Adoptive Cellular Therapy
Price: 2999.00
Date: July 2021

Adoptive Cellular Therapy: Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Adoptive Cellular Therapy:
Adoptive cell therapy, also known as cellular immunotherapy, is a form of treatment that uses the cells of our immune system to eliminate cancer.

Some of these approaches involve directly isolating our own immune cells and simply expanding their numbers, whereas others involve genetically engineering our immune cells (via gene therapy) to enhance their cancer-fighting capabilities.

Our immune system is capable of recognizing and eliminating cells that have become infected or damaged as well as those that have become cancerous. In the case of cancer, immune cells known as killer T cells are particularly powerful against cancer, due to their ability to bind to markers known as antigens on the surface of cancer cells. Cellular immunotherapies take advantage of this natural ability and can be deployed in different ways:

Tumor-Infiltrating Lymphocyte (TIL) Therapy
Engineered T Cell Receptor (TCR) Therapy
Chimeric Antigen Receptor (CAR) T Cell Therapy
Natural Killer (NK) Cell Therapy
 
Top & Promising Drugs by Company:
Gilead Sciences Inc- Yescarta (axicabtagene ciloleucel)
Novartis AG- Kymriah (tisagenlecleucel)
TCR2 Therapeutics Inc- (TC-210)
Fate Therapeutics Inc- (FT-538)
Cellectis SA- (UCART-123)
Ace Technologies Corp- (CTX-110)
Teva Pharmaceutical Industries Ltd- Vigil (Provigil)
Hadasit Bio-Holdings Ltd- (ApoCell)
Dendreon Pharmaceuticals LLC- Provenge (sipuleucel-T)
Autolus Therapeutics Plc- (AUTO-3)